Immunotherapy for epilepsy

References

• Rogers SW, Andrews PI, Gahring LC et al. 1994. Autoantibodies to glutamate receptor G1uR3 in Rasmussen's encephalitis. Science 265, 648-651 (1994).
   PubMedGoogle Scholar
• ••First report that immunization of rabbitswith GiuR3 produced epileptic seizures and inflammatory histopathology mimicking human RE. Since then, however, no study in any species has reproduced the finding that GiuR3 immunization causes epilepsy.
   Google Scholar
• Rasmussen T, Olszweski J, Lloyd-Smith DL. Focal seizures due to chronic localized encephalitis. Neurology 8, 435–445 (1958).
   Google Scholar
• •Why Rasmussen's is an eponymous syndrome.
   Google Scholar
• Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology44\(Suppl. 8), S14-523 (1994).
   Google Scholar
• Chapman AG. Glutamate receptors in epilepsy. Prog. Brain Res. 116, 371–383 (1998).
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Baggi F, Antozzi C et al. Anti-glutamate receptor 3 (G1uR3) antibodies: frequency and association with epilepsy. j NeuroimmunoL 118, 140 (2001). Abstract.
   Google Scholar
• Bernasconi P, Passerini L, Baggi, F eta]. Anti- glutamate receptor 3 antibodies seem to be associated with severe forms of epilepsy rather than with Rasmussen's encephalitis. AutoimmuniO, Rev 1, 70 (2002).
   Google Scholar
• Watson R, Beeson D, Bermudez I et al. Autoantibodies in Rasmussen's encephalitis. Autoimmunity Rev. 1, 70 (2002).
   Google Scholar
• Wiendl H, Bien CG, Bernasconi P et al. G1uR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 57, 1511–1514 (2001).
   PubMed Web of Science ®Google Scholar
• Gahring LC, Twyman RE, Greenlee JE, Rogers SW Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. MoL Med. 1, 245–253 (1995).
   PubMed Web of Science ®Google Scholar
• Gahring LC, Rogers SW, Twyman RE. Autoantibodies to glutamate receptor subunit G1uR2 in nonfamilial olivopontocerebellar degeneration. Neurology 48, 494–500 (1997).
   Google Scholar
• Sillevis Smitt P, Kinoshita A, De Leeuw B et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl. j Med. 342, 21–27 (2000).
   Google Scholar
• Dambinova SA, Izykenova GA, Burov SV eta]. The presence of autoantibodies to N-terminus domain of G1uR1 subunit of AMPA receptor in the blood serum of patients with epilepsy. j NeuroL Sci. 152, 93 (1997).
   Google Scholar
• DeGiorgio LA, Konstantinov KN, Lee SC et al. A subset of lupus antiDNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189–1193 (2001).
   Google Scholar
• Twyman RE, Gahring LC, Spiess J eta]. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 14, 755–762 (1995).
   Google Scholar
• ••First demonstration that antiGluR3antibodies can act as glutamate agonists, activate GluR and evoke ion currents. Based on these observations, it was suggested that antiGluR3 antibodies can mimic the actions of excess glutamate and cause excitotoxic neuronal death.
   Google Scholar
• Levite M, Fleidervish IA, Schwarz A eta]. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel.' Autaimmun. 13, 61–72 (1999).
   Google Scholar
• ••Only currently existing murine model forantiGluR3 immunity, which showed for the first time that purified antiGluR3 can kill neurons. Killing occurred via activation of GluR and was complement-independent. However, neuronal death did not lead to detectable epilepsy.
   Google Scholar
• Koustova EY, Sei L, Fossom ML eta]. LP- BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor. j Clin. Invest. 107, 737–744 (2001).
   Google Scholar
• ••First solid evidence that a specific viralinfection led (by partial molecular mimicry) to the in vivo production of antiGluR antibodies that bound, activated and killed neurons.
   Google Scholar
• Levite M, Hermelin A. Autoimmunity to the glutamate receptor in mice - a model for Rasmussen's encephalitis? j Autoimmun. 13, 73–82 (1999).
   Google Scholar
• Whitney K, McNamara JO. G1uR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. j Neurosci. 20(19), 7307–7316 (2000).
   Google Scholar
• Gahring L, Carlson NG, Meyer EL eta]. Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. j ImmunoL 166, 1433–1438 (2001).
   Google Scholar
• ••Important and elegant study that showedfor the first time how the autoantigenic peptide, G1uR3B, can be cleaved from its parent GluR3 protein. This cleaved peptide may subsequently lead to the production of pathogenic antiGluR3B antibodies.
   Google Scholar
• Li Y, Uccelli A, Laxer KD et al. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. j ImmunoL 158, 1428–1437 (1997).
   PubMed Web of Science ®Google Scholar
• Prayson RA, Frater JL. Rasmussen encephalitis: a clinicopathologic and immunohistochemical study of seven patients. Am. J Clin. PathoL 117, 776–782 (2002).
   PubMed Web of Science ®Google Scholar
• Bien CG, Bauer J, Deckwerth TL eta]. Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in Rasmussen's encephalitis. Ann. NeuroL 311–318 (2002).
   Google Scholar
• Neumann H, Medana IM, Bauer J et aL Cytotoxic T-lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25, 313–319 (2002).
   PubMed Web of Science ®Google Scholar
• •Important review of the current evidence supporting the involvement of cytotoxic T-cells in several neurological diseases, including RE.
   Google Scholar
• Archelos JJ, Hartung HP Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 23,317–327 (2000).
   PubMed Web of Science ®Google Scholar
• Levite M. Autoimmune epilepsy. Nat. ImmunoL 3, 500 (2002).
   PubMed Web of Science ®Google Scholar
• Dulac 0, Robain 0, Chiron C eta]. High-dose steroid treatment of epilepsia partialis continua due to chronic focal encephalitis. In:Chronic encephalitis and epilepsy - Rasmusvni syndrome. Andermann F (Ed.), Butterworth-Heinemann, Boston, USA, 193–199 (1991).
   Google Scholar
• Hart YM, Cortez M, Andermann F eta]. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44, 1030–1036 (1994).
   Google Scholar
• ••Treatment guidelines based on one of theearliest and largest open-label studies of immunotherapy in RE.
   Google Scholar
• Krauss GL, Campbell ML, Roche KW eta]. Chronic steroid-responsive encephalitis without autoantibodies to glutamate receptor G1uR3. Neurology 46, 247–249 (1996).
   Google Scholar
• Andrews PI, Dichter MD, Berkovic SF eta]. Plasmapheresis in Rasmussen's encephalitis. Neurology 46, 242–246 (1996).
   Google Scholar
• Antozzi C, Granata T, Aurisano 0 eta]. Long-term selective IgG irnmuno-adsorption improves Rasmussen's encephalitis. Neurology 51, 302–305 (1998).
   Google Scholar
• Antozzi C, Granata T, Bernasconi P eta]. Apheresis and irnmunomodulatory treatments in Rasmussen's encephalitis: the Italian experience. AutoimmuniO, Rev 1, 24 (2002).
   Google Scholar
• Leach JP, Chadwick DW, Miles JB et al. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 52, 738–742 (1999).
   PubMed Web of Science ®Google Scholar
• Hart IK, Chadwick DVV, Smith D. Adult Rasmussen's syndrome improves with immune therapy. Neuroimmund 118, 144 (2001).
   Google Scholar
• Van Engelen BG, Renier WO, Weemaes CM et al. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gestaut syndrome; an add-on study. Eur j Pediat. 153, 762–769 (1994).
   PubMed Web of Science ®Google Scholar
• Van Rijckevorsel-Harmant K, Delire M, Rucquoy-Ponsar M. Treatment of idiopathic West and Lennox-Gestaut syndromes by iv. administration of human polyvalent inmmunoglobulins. Eur. Arch. Psych. NeuroL Sci. 236, 119–122 (1985).
   Google Scholar
• Ariizumi M, Baba K, Hibio S et al. Immunoglobulin therapy in the West syndrome. Brain & Development 9, 422–425 (1987).
   PubMed Web of Science ®Google Scholar
• Duse M, Notarangelo LD, Tiberti S eta]. Intravenous immune globulin therapy in the treatment of intractable childhood epilepsy. Clin. Exp. Immunol 104 (51), 71–76 (1996).
   Google Scholar
• •Review of the 29 studies of immunotherapy in 373 children with severe epilepsy that suggests useful improvement in 30-50% of cases.
   Google Scholar
• Echenne B, Dulac 0, Parayre-Chanez MJ et aL treatment of infantile spasms with iv. gamma-globulins. Brain & Development 13, 313–319 (1991).
   Google Scholar
• Lagae LG, Silberstein J, Gillis PL et al. Successful use of iv. immunoglobulins in Landau-Kleffner syndrome. Pediatr. NeuroL 18, 165–168 (1998).
   PubMed Web of Science ®Google Scholar
• Mikati MA, Saab R. Successful use of iv. immunoglobulin as initial monotherapy in Landau-Kleffner syndrome. Epilepsia 41, 880–886 (2000).
   Google Scholar
• Palace J, Lang B. Epilepsy: an autoimmune disease? J NeuroL Neurosurg. Psychiatry 69, 711–714 (2000).
   Google Scholar
• Bartolomei F, Boucraut J, Barrie M eta]. Cryptogenic partial epilepsies with antiGM1 antibodies: a new form of immune-mediated epilepsy? Epilepsia 37, 922–926 (1996).
   Google Scholar
• Giometto B, Nicolao P, Macucci M et al. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet (letter) 352, 457 (1998).
   PubMed Web of Science ®Google Scholar
• Lousa M, Sanchez-Alonsos S, Rodriguez-Diaz C et al. Status epilepticus with neuron-reactive serum antibodies: response to plasma exchange. Neurology54, 2163–2165 (2000).
   PubMed Web of Science ®Google Scholar
• Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci. 23 (51), 533—S37 (2002).
   Google Scholar